Condition: Non-small Cell Lung Cancer · Sponsor: OBI Pharma, Inc
This study is a randomized, active control, open-label, phase 2 trial. Erlotinib-treated NSCLC patients will be screened for Globo H, and only Globo H+ (H score ≥ 100) subjects are eligible for the study. Eligible subjects who have been treated with 3±1 months of first-line erlotinib and have achieved stable disease (SD) or partial response (PR) status will be randomized in the ratio of 1:1 to receive erlotinib alone or erlotinib plus OBI-833/OBI-821 therapy.
This description comes directly from the study's public registry record.
Anna Hu · 886-2-27866589 · annahu@obipharma.com
Lance Ou · 886-2-27866589 · lou@obipharma.com
Always discuss trial participation with your own doctor first.
| Taipei Veterans General Hospital | Taipei, Beitou District, Taiwan | Recruiting |
| National Taiwan University Cancer Center | Taipei, Da'an Dist., Taiwan | Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Guishan Dist., Taiwan | Recruiting |
| Tri-Service General Hospital | Taipei, Neihu District, Taiwan | Recruiting |
| Shuang Ho Hospital | New Taipei City, Zhonghe District, Taiwan | Recruiting |
| National Taiwan University Hospital | Taipei, Zhongzheng Dist., Taiwan | Recruiting |
| Taichung Veterans General Hospital | Taichung, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05442060